New York, NY. November 23, 2021 – Last night’s Lupus Research Alliance (LRA) Breaking Through Gala was the most successful in the history of the organization raising $7.5 million – double that of any previous year — for lupus research. The hundreds attending the hybrid festivities in-person at the Ziegfeld Ballroom and online were inspired by […] READ MORE
NEW YORK, NY. September 30, 2021. The Lupus Research Alliance (LRA) is pleased to invite the global community to join together as one at its virtual ManyOne Can. Walk with Us to Cure Lupus celebratory event. The aim is to unite and inspire the entire world on one day, Saturday, October 2, 2021, to achieve one […] READ MORE
This Largest-Ever Grant Will Fund Two Projects Examining Why Lupus Differs for Each Person NEW YORK, NY. Sept. 21. Today, the Lupus Research Alliance is pleased to announce the inaugural recipients of its largest grant to date, the Global Team Science Award, which will fund international, multidisciplinary research teams to unravel lupus heterogeneity with the […] READ MORE
Research Funded by the Lupus Research Alliance Published in Today’s “Cell” NEW YORK, NY August 11. Pediatric lupus expert Virginia Pascual, MD together with her junior colleague Simone Caielli, PhD and their team at Weill Cornell Medicine in New York identified problems in the red blood cells of children with active Systemic Lupus Erythematosus […] READ MORE
First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] READ MORE
Research Is First to Pinpoint a Gut Organism to Lupus, Advancing Understanding of the Microbiome in Autoimmune Disease NEW YORK, NY. June 9. The Lupus Research Alliance (LRA) announced today that Martin Kriegel, MD, PhD, of the University of Münster is the 2021 Lupus Insight Prize Awardee for his cutting edge research in the understanding […] READ MORE
SUMMIT, NJ — May 3. In honor of May, Lupus Awareness Month, former Super Bowl Champion and Barstool Sports radio personality Willie Colon, hosted the annual Willie Colon Golf Outing for the Lupus Research Alliance (LRA). Dedicated to advancing lupus research, Mr. Colon is a member of the Lupus Research Alliance Board of Directors. In […] READ MORE
Dr. Eric Morand Publishes Results Funded by LRA’s Distinguished Innovator Award NEW YORK, NY. March 31, 2021. Results of critical work funded by the Lupus Research Alliance Distinguished Innovator Award to Dr. Eric Morand suggests a path toward making lupus treatment with glucocorticoids (steroids) effective at lower doses, lessening harmful side effects. In a study […] READ MORE
NEW YORK, March 25, 2021 — The Lupus Research Alliance proudly announces two exceptional recipients of the 2020 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: Jacques Banchereau, PhD and Ignacio Sanz, MD. Both projects funded by this grant are investigating different mechanisms altered in lupus patients that induce an autoimmune response. Their findings […] READ MORE
First Joint Common Mechanisms Grants Announced NEW YORK, NY, February 24, 2021 – JDRF International, the Lupus Research Alliance and the National Multiple Sclerosis Society joined forces to accelerate research and discovery in autoimmunity and are proud to announce the recipients of their first joint grants. Called Decoding Immune-Mediated Diseases – Novel Approaches for Therapeutic […] READ MORE
First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […] READ MORE
NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […] READ MORE
